Oncodesign Reacquires Rights to OPM-201 After Positive Phase 1 Trial
Oncodesign Precision Medicine (OPM) has regained full rights to its Parkinson’s disease treatment program, OPM-201, after Servier Laboratories shifted...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trial Quality Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Oncodesign Precision Medicine (OPM) has regained full rights to its Parkinson’s disease treatment program, OPM-201, after Servier Laboratories shifted...
MIRAILAB BIOSCIENCE Inc., a Tokyo-based company specializing in NMN supplements, has partnered with Global Ocean Distribution Pte Ltd to...
Ellipses Pharma has launched its first large-scale Phase 1/2 oncology clinical trial in the United Arab Emirates (UAE) for...
The SCOPE Summit has revealed the six finalists for its highly anticipated 2025 Participant Engagement Awards, celebrating excellence in...
TIXiMED, a clinical-stage pharmaceutical company, has secured a $2.65 million loan from the Helmsley Charitable Trust to advance its...
Tolerance Bio, Inc., a biopharmaceutical company, has formed a Scientific Advisory Board and completed a $20.2 million seed financing...
Colorado’s life sciences ecosystem flourished in 2024, raising $2.15 billion, a 46% increase from 2023, marking the second time...
BiVACOR, a clinical-stage medical device company, has successfully completed the initial phase of its FDA Early Feasibility Study (EFS)...
Insitro, a machine learning-driven drug discovery company, achieved a milestone in its collaboration with Bristol Myers Squibb, receiving $25...
Holoclara, a biotechnology company, has launched its first-in-human Phase 1 clinical trial for HC002, an orally available small molecule...